Drug Trial Radar · NCT07490301
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
900
Planned (sponsor's estimate)
Start
Apr 30, 2026
Primary completion
Jun 2031
Study completion Jun 2031
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The pancreas is a gland behind the stomach that produces a digestive fluid that is emptied into the intestines through tube shaped ducts. Pancreatic cancer often starts in these ducts. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan when given in combination with fluorouracil, folinic acid, and oxaliplatin (FOLFOX) to treat adult participants with pancreatic ductal cancer. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of pancreatic ductal adenocarcinoma (PDAC). This study will be divided into two phases, with the first phase (Phase 2) treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX. Participants will then be randomized into 3 groups called treatment arms. Two groups will receive telisotuzumab adizutecan with FOLFOX with different optimized doses. One group will receive standard of care (SOC) - fluorouracil, leucovorin, oxaliplatin, and irinotecan. In the second phase (Phase 3), participants will be randomized into 2 arms to receive either the optimal dose of telisotuzumab adizutecan (from the previous phase) with FOLFOLX, or SOC. Approximately 900 participants with PDAC will be enrolled in this study in approximately 200 sites worldwide. Phase 2 includes a dose escalation stage and a dose optimization stage. In the dose escalation stage, participants will receive escalating doses of Intravenous (IV) telisotuzumab adizutecan + FOLFOX. In the dose optimization stage, participants will receive 1 of 2 doses of IV telisotuzumab adizutecan with FOLFOX or SOC. At the start of Phase 3, participants will receive the optimal dose of IV telisotuzumab adizutecan with FOLFOX or SOC. The study will run for a duration of approximately 6 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- PDAC
Interventions
Telisotuzumab adizutecanDrug
Intravenous (IV) Infusion
FluorouracilDrug
IV Infusion
Folinic acid/ LeucovorinaDrug
IV Infusion
OxaliplatinDrug
IV Infusion
IrinotecanDrug
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2 and Phase 3: Overall Response (OR) Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: through study completion, approximately 6 years
- Phase 3: Overall Survival (OS)Time frame: through study completion, approximately 6 years
Locations
22 sites in 8 countries. Site status is shown where the registry gives one.
Smilow Cancer Center At Yale-New Haven /ID# 279780
New Haven, Connecticut · Recruiting
University of Chicago Medical Center /ID# 279460
Chicago, Illinois · Recruiting
City Of Hope - Chicago /ID# 279814
Zion, Illinois · Recruiting
Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 279853
Grand Rapids, Michigan · Recruiting
Washington University /ID# 279890
St Louis, Missouri · Recruiting
UH Seidman Cancer Center /ID# 279602
Cleveland, Ohio · Recruiting
University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 280038
Philadelphia, Pennsylvania · Recruiting
Texas Oncology - Northeast Texas /ID# 280417
Tyler, Texas · Recruiting
Virginia Cancer Specialists - Fairfax /ID# 280415
Fairfax, Virginia · Recruiting
Austin Hospital /ID# 280283
Melbourne, Victoria, Australia · Recruiting
Rambam Health Care Campus- Haifa /ID# 279409
Haifa, Israel · Recruiting
Hadassah Medical Center-Hebrew University /ID# 279411
Jerusalem, Israel · Recruiting
The Chaim Sheba Medical Center /ID# 279408
Ramat Gan, Tel Aviv, Israel · Recruiting
Tel Aviv Sourasky Medical Center /ID# 279414
Tel Aviv, Tel Aviv, Israel · Recruiting
The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 280140
Koto-ku, Tokyo, Japan · Recruiting
Unidade Local de Saude de Santa Maria /ID# 279884
Lisbon, Portugal · Recruiting
Fundacao Champalimaud /ID# 279881
Lisbon, Lisbon District, Portugal · Recruiting
Seoul National University Hospital /ID# 280191
Seoul, Seoul Teugbyeolsi, South Korea · Recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 279735
Kaohsiung City, Taiwan · Recruiting
China Medical University Hospital /ID# 279725
Taichung, Taiwan · Recruiting
Taipei Veterans General Hospital /ID# 279726
Taipei, Taiwan · Recruiting
Oxford University Hospital NHS Trust /ID# 279764
Oxford, Oxfordshire, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.